全部

1·Most patients will not die from follicular lymphoma, and that's very reassuring.

大部分患者将不会死于滤泡性淋巴瘤，这是非常肯定的。

2·We describe the clinicopathologic features of 88 cases of CD5+ follicular lymphoma (53 men, 35 women;

作者描述88例CD5+的滤泡性淋巴瘤临床病理学特征（男性53例，女性35例；

3·Objective To discuss the differential diagnosis between tumor-like follicular hyperplasia and follicular lymphoma.

目的讨论淋巴滤泡瘤样增生与滤泡性淋巴瘤的鉴别诊断。

4·The PI3K deltainhibitor idelalisib (Zydelig) and the BTK inhibitor ibrutinib (Imbruvica) have shown promise for patients with relapsed follicular lymphoma.

PI3K抑制剂idelalisib和BTK抑制剂ibrutinib对复发的滤泡性淋巴瘤显示出很好的潜力。

5·INTERPRETATION: 2 years of rituximab maintenance therapy after immunochemotherapy as first-line treatment for follicular lymphoma significantly improves PFS.

阐释：滤泡性淋巴瘤患者在免疫化疗作为一线治疗后使用利妥昔单抗维持治疗2年，能显著改善无进展生存（PFS）。

6·If your disease does not respond to initial treatment, your treatment options are detailed below under Treatment of Recurrent or Refractory Follicular Lymphoma.

如果你的肿瘤对初始治疗无效，你的治疗选择详见复发或难治性滤泡淋巴瘤的治疗部分。

7·In addition to representing a potential biomarker, the existence of cells with defective BCR signaling may provide new targets against follicular lymphoma. -jcl.

除了代表潜在的生物标记物外，伴有缺陷BCR信号的细胞存在可提供滤泡性淋巴瘤新的靶点。

8·In a small 30-patient study, pidilizumabplus rituximab demonstrated an ORR of 66% in relapsed follicular lymphoma, which primarily consisted of complete responses.

在一个30例患者的小规模研究中，pidilizumab加利妥昔单抗在复发的滤泡性淋巴瘤中取得了66%的总有效率，其中大部分是完全缓解。

9·Additionally, a phase II study is looking at the combination of rituximab and pembrolizumab (Keytruda) for patients with relapsed follicular lymphoma (NCT02446457).

此外，一项二期研究将利妥昔单抗和pembrolizumab联合来治疗复发的滤泡性淋巴瘤。

10·Watch and wait (WAW) is a common approach for asymptomatic, advanced stage follicular lymphoma (FL), but single-agent rituximab is an alternative for these patients.

观察等待是无症状的晚期滤泡性淋巴瘤常用的策略，但是对于这些患者来说美罗华单药治疗也是一个选项。